ArticleFrontiers in medicine2026
Real-world skin and dermatology-specific quality-of-life outcomes and a nomogram to predict skin response to secukinumab in Chinese psoriatic arthritis patients: a multicenter retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Real-world data on secukinumab in Chinese psoriatic arthritis (PsA) patients remain limited, particularly regarding short-term cutaneous response, dermatology-specific quality of life, and predictors of treatment response. Methods: A retrospective cohort study was performed using 446 PsA patients diagnosed based on the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria and treated with secukinumab for >12 weeks. Skin severity and quality of life were assessed using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Investigator's Global Assessment (IGA), and Dermatology Life Quality Index (DLQI) at baseline and after treatment. Treatment-related adverse events (TRAEs) were graded according to CTCAE v5.0. A predictive nomogram was constructed using stepwise multivariate regression and validated using the receiver operating characteristic (ROC) analysis. Results: The cohort of 446 PsA patients (mean age 47.7 years; 65.2% men) exhibited significant improvements across all domains. Post-treatment PASI decreased from 14.2 ± 14.4 to 3.98 ± 8.84 ( Conclusion: In this real-world cohort of Chinese PsA patients, secukinumab demonstrates robust clinical short-term efficacy in skin severity and dermatology-specific quality of life, with a favorable short-term safety profile. The predictive nomogram may assist in estimating short-term cutaneous response, although external validation is required. However, these findings are specific to PsA patients and should not be extrapolated to psoriasis populations without musculoskeletal involvement, given the additional disease-burden dimensions in PsA that influence quality-of-life outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.